Recurrent C. Difficile Infections (rCDI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Clostridium difficile infection (CDI) arises from an anaerobic spore-forming bacillus inhabiting the intestinal tract, primarily in individuals whose normal gut microbiota is disrupted by antibiotic therapy or other factors. This bacterium, C. difficile, secretes two principal toxins—toxins A and B—resulting in intestinal mucosal damage, diarrhea, and colitis. Severe cases may progress to shock, ileus, and toxic megacolon. In high-income nations, C. difficile is the foremost cause of infectious diarrhea among hospitalized patients. Advanced age stands out as the most frequently cited risk factor for recurrent CDI (rCDI). In a retrospective analysis, the likelihood of rCDI stood at 25.0%, 27.1%, and 58.4% for individuals aged 0 to 17, 18 to 64, and ≥65 years, respectively. Among modifiable risk factors, antibiotic use for non-C. difficile infections post-CDI diagnosis ranks foremost. Furthermore, the use of gastric acid suppression has been linked to an increased risk of rCDI. These suppressive agents, commonly employed to prevent stress ulcers or treat acid-related conditions, may compromise the body's defenses against C. difficile, elevating the CDI risk. Additional risk factors encompass severe underlying ailments, renal insufficiency, prior CDI occurrences, prolonged hospital stays, and inadequate adaptive immune responses to toxins A and B. Initial antibiotic treatment failure affects 20% to 35% of CDI patients, with 40% to 60% experiencing a second recurrence after that. Such recurrences incur significant morbidity and impose a substantial burden on healthcare systems. Multiple treatment options, such as vancomycin, fidaxomicin, and fecal microbiota transplant (FMT), are recommended for managing rCDI. Recurrent CDI impacts 15-35 percent of CDI patients, often manifesting as a relapse of the original infection rather than a new strain. Following the first recurrence, subsequent recurrences become even more commonplace.

 

Thelansis’s “Recurrent C. Difficile Infections (rCDI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent C. Difficile Infections (rCDI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Recurrent C. Difficile Infections (rCDI) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Recurrent C. Difficile Infections (rCDI) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Recurrent C. Difficile Infections (rCDI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033